July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Cell derived matrices modulate TGFβ2 signaling in human trabecular meshwork cells
Author Affiliations & Notes
  • Felix Yemanyi
    Department of Basic Sciences, University of Houston College of Optometry, Houston, Texas, United States
  • Janice A Vranka
    Department of Ophthalmology, Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, United States
  • VijayKrishna Raghunathan
    Department of Basic Sciences, University of Houston College of Optometry, Houston, Texas, United States
    Department of Biomedical Engineering, Cullen College of Engineering, University of Houston, Houston, Texas, United States
  • Footnotes
    Commercial Relationships   Felix Yemanyi, None; Janice Vranka, None; VijayKrishna Raghunathan, None
  • Footnotes
    Support  NIH T35 student Vision Research Support Grant (sVRSG), Bright Focus National Glaucoma Research Award (VKR), and NIH/NEI grant 1 R01 EY026048-01A1 (VKR/JAV).
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 5146. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Felix Yemanyi, Janice A Vranka, VijayKrishna Raghunathan; Cell derived matrices modulate TGFβ2 signaling in human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 2019;60(9):5146.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Aberrant trabecular meshwork (TM) extracellular matrix (ECM) remodeling is an important causal risk factor for ocular hypertension. The molecular consequences of remodeled ECM or their role in mediating cellular responses to pro-fibrotic cytokines in TM pathobiology is unknown. Given the well-established role of TGFβ2 signaling in POAG, we sought to determine how cell derived matrices modulate human TM (hTM) cell behavior and whether this occurs via Smad- and/or Non-Smad-dependent TGFβ2 signaling pathways.

Methods : Primary hTM cells (n=3 donors) were cultured for 4 weeks in the absence/presence of dexamethasone to obtain vehicle control (VehM) and glaucoma-mimetic (GMM) cell derived matrices respectively. Subsequently, a fresh batch of hTM cells from the same donor was seeded on the VehM and GMM decellularized matrices in media containing 1% FBS ± 5ng/ml TGFβ2 treatment for up to 7 days. Changes in protein expression were quantified at 4 individual timepoints.

Results : Smad pathway: In the absence of TGFβ2, Smad2 expression was increasingly elevated at 5d (~1.4 fold) and 7d (~1.65 fold, p<0.05 ANOVA), while pSmad2 was elevated at 7d (~2.45 fold, p<0.05 ANOVA) in hTM cells plated on GMM compared with VehM. In the presence of TGFβ2, Smad2/3 and pSmad2 protein levels were all downregulated (~0.5 fold, p<0.05 ANOVA) in hTM cells cultured on both VehM and GMM at all time points, although the inhibition was more pronounced for Smad3 and in cells seeded on GMM. Non-Smad pathway: In the absence of TGFβ2, pERK1/2 was elevated at all timepoints; in the presence of TGFβ2, it was increased from 1d to 5d in hTM cells on GMM. Concurrently, differential temporal expression patterns were noticed for P38, pP38, JNK2 and pJNK. In contrast, RhoA was first inhibited at 1d in the absence and presence of TGFβ2, and subsequently upregulated significantly with increasing time; although changes via GMM in the absence of TGFβ2 were greater than in its presence.

Conclusions : These results strongly demonstrate that cell derived ECM potently modulates intrinsic signaling in hTM cells, as well as differentially regulating cellular responses to exogenous TGFβ2. Understanding the consequences of the altered ratio of Smad- to Non-Smad-dependent signaling in hTM cells will require further investigations. These results are important, since TGFβ2 levels are elevated in the aqueous humor in POAG whilst the TM tissue is being actively remodeled.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×